NewsBenzingaRBC Capital mantiene su recomendación de sobreponderar sobre Cormedix y reduce el precio objetivo a 14 dólares RBC Capital mantiene su recomendación de sobreponderar sobre Cormedix y reduce el precio objetivo a 14 dólares Benzinga 2026.11.13 15:22 (GMT+0) Open on Benzinga Other news Israeli Shipping Giant ZIM Cashes In on Surging Freight Rates, Raises Outlook UBS Maintains Buy on Home Depot, Lowers Price Target to $417 Disney Posts Upbeat Q4, Analysts Raise Price Target Citing Theme Park Resilience StoneX Maintains Buy on Bitdeer Techs, Lowers Price Target to $15 Merck Pulls Plug On Acquired Drug after Safety Review UBS Maintains Neutral on Granite Point Mortgage Tr, Lowers Price Target to $3